At what enterprise value was PARAGON MEDICAL acquired in 2023?

During the acquisition of PARAGON MEDICAL by AMETEK in 2023, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PARAGON MEDICAL when it was acquired by AMETEK?

The estimated EV/EBITDA multiple for PARAGON MEDICAL is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was PARAGON MEDICAL acquired by AMETEK?

PARAGON MEDICAL was acquired by AMETEK in 2023.

What was the revenue of PARAGON MEDICAL at the time of the deal?

The revenue of PARAGON MEDICAL at the time of the deal is estimated to be in the range of 450M - 900M USD. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of PARAGON MEDICAL during the acquisition?

PARAGON MEDICAL's EBITDA is estimated to be in the range of 100M - 200M USD. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PARAGON MEDICAL acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PARAGON MEDICAL deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ametek.fr/newsroom/news/investor/2023/december/ametek-completes-acquisition-of-paragon-medical

← DATABASE

Home Database Healthcare & PharmaPARAGON MEDICAL

11/2023

PARAGON MEDICAL acquired by AMETEK

UNITED STATES Life Sciences / Medical Devices EV 1b - 4b USD

Context

Paragon Medical has been acquired by AMETEK. This successful acquisition represents a significant tactical expansion of the group’s capabilities within the high-growth healthcare technology sector. Paragon Medical will join AMETEK’s Electromechanical division, creating a more diversified portfolio of mission-critical medical solutions. The strategic rationale hinges on the fusion of Paragon Medical’s leadership in surgical instrumentation and implantable components with AMETEK’s global reach and industrialized operating model. This operation will enable AMETEK to reinforce its ability to address the increasing demand for advanced orthopedic and robotic surgical tools driven by aging global demographics and the shift toward minimally invasive procedures.

By taking control of Paragon Medical, Ametek continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Gatan in 2019.

PARAGON MEDICAL, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Paragon Medical functions as a premier technology-driven organization specializing in the design, engineering, and manufacturing of critical medical components and surgical instruments. The entity’s business model is built on an industrialized framework as a contract development and manufacturing organization (CDMO), providing technical operational depth to global medical device leaders. Its value proposition is anchored in high-precision micro-machining and specialized metallurgy for orthopedic implants, robotic surgical tools, and drug delivery systems. Strategically, the firm focuses on being a mission-critical partner in the healthcare supply chain, offering end-to-end solutions from prototyping to high-volume commercial production. By maintaining a diverse portfolio of single-use instruments and implantable hardware, the organization ensures the structural reliability of advanced therapeutic procedures. The entity prioritizes manufacturing excellence and technical agility to facilitate the rapid scaling of medical innovations in a highly regulated landscape.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with PARAGON MEDICAL

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2020	AMERICAN SECURITIES	PARAGON MEDICAL	UNITED STATES	Life Sciences	The divestiture of the Life Sciences division by NN inc. (Paragon Medical) to American Securities represents a pivotal structural transformation for both organizations. For the seller, the transaction provides a necessary capital infusion to significantly reduce corporate debt and reposition its remaining industrial platform toward power and mobile solutions
05/2018	NN	PARAGON MEDICAL	UNITED STATES	Life Sciences	The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets

REFERENCES

Valuation range: EV 1b - 4b USD

Revenue range: 450M - 900M USD

EBITDA range: 100M - 200M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PARAGON MEDICAL by AMETEK are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: paragon medical

Acquirer: ametek